Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium Tc 99m trofolastat

Drug Profile

Technetium Tc 99m trofolastat

Alternative Names: 1404; 99mTc-MIP1404; 99mTc-trofolastat; F-1311; MIP-1404; MP-1404; PSMA-targeted imaging agent 1404

Latest Information Update: 21 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer FUJIFILM Toyama Chemical; Molecular Insight Pharmaceuticals
  • Class Antineoplastics; Imaging agents; Imidazoles; Organotechnetium compounds; Radiopharmaceuticals; Small molecules; Technetium compounds
  • Mechanism of Action Diagnostic imaging enhancers; Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 14 May 2019 Technetium Tc 99m trofolastat licensed to ROTOP Pharmaka in Europe
  • 14 May 2019 ROTOP Pharmaka intends to have a meeting with the European regulatory authorities in early 2020
  • 14 May 2019 ROTOP Pharmaka plans a clinical trial in early 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top